Daré Bioscience (NASDAQ:DARE) Shares Cross Below 200-Day Moving Average – Should You Sell?

Daré Bioscience, Inc. (NASDAQ:DARE) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.33 and traded as low as $2.88. Daré Bioscience shares last traded at $2.88, with a volume of 15,094 shares changing hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Daré Bioscience in a report on Tuesday, December 17th.

Daré Bioscience Price Performance

The firm has a market capitalization of $25.06 million, a price-to-earnings ratio of -4.88 and a beta of 1.38. The stock has a fifty day moving average of $3.15 and a two-hundred day moving average of $3.33.

Institutional Trading of Daré Bioscience

A number of large investors have recently bought and sold shares of DARE. AMH Equity Ltd grew its holdings in Daré Bioscience by 50.0% during the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock worth $468,000 after acquiring an additional 50,000 shares during the period. Jane Street Group LLC acquired a new stake in Daré Bioscience during the 4th quarter worth about $52,000. Renaissance Technologies LLC grew its holdings in Daré Bioscience by 6.7% during the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock worth $214,000 after acquiring an additional 4,300 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Daré Bioscience by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after acquiring an additional 3,593 shares during the period. 6.70% of the stock is currently owned by institutional investors and hedge funds.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.